You are here

Article Text

Article menu
Download PDFPDF
Letter
Association between pancreatic cancer and metformin use in patients with type 2 diabetes
  1. Shih-Wei Lai1,2,
  2. Chia-Hsun Tsai3,
  3. Cheng-Li Lin1,4,
  4. Kuan-Fu Liao3,5
  1. 1 College of Medicine, China Medical University, Taichung city, Taiwan
  2. 2 Department of Family Medicine, China MedicalUniversity Hospital, Taichung city, Taiwan
  3. 3 Division of Hepatogastroenterology, Department of Internal Medicine, Taichung Tzu Chi Hospital, Taichung city, Taiwan
  4. 4 Management Office for Health Data, China Medical University Hospital, Taichung city, Taiwan
  5. 5 College of Medicine, Tzu Chi University, Hualien, Taiwan
  1. Correspondence to Dr Kuan-Fu Liao, Taichung Tzu Chi Hospital, Taichung City 427, Taiwan; kuanfuliaog{at}gmail.com
View Full Text

http://dx.doi.org/10.1136/postgradmedj-2019-136463

Statistics from Altmetric.com

    One cohort study revealed that patients with type 2 diabetes with metformin use had a lower risk of developing pancreatic cancer (HR 0.49, 95% CI 0.25 to 0.96).1 One meta-analysis revealed that patients with type 2 diabetes with metformin use had a lower mortality of pancreatic cancer (risk ratio 0.84, 95% CI 0.73 to 0.96) .2 However, one cohort study revealed no significant association between metformin use and pancreatic cancer (HR 0.85, 95% CI 0.39 to 1.89).3 Another cohort study revealed no significant association between metformin use and survival of pancreatic cancer (HR 0.86, 95% CI 0.66 to 1.11).4 Conflicting findings exist on this issue. In order to clarify these debates, a population-based case–control study was designed to analyse the database of …

    View Full Text

    Footnotes

    • Contributors S-WL and C-HT initiated the draft of the article, revised the article and contributed equally to the article. C-LL and K-FL conducted the data analysis.

    • Funding This study was supported in part by the Ministry of Health and Welfare in Taiwan (MOHW108-TDU-B-212-133004) and China Medical University Hospital in Taiwan (DMR-107-192).

    • Disclaimer The funding agencies did not influence the study design, data collection and analysis, decision to publish or preparation of the manuscript.

    • Competing interests None declared.

    • Patient consent for publication Not required.

    • Ethics approval This study was approved by the Research Ethics Committee of China Medical University and Hospital in Taiwan (CMUH-104-REC2-115).

    • Provenance and peer review Not commissioned; internally peer reviewed.

    • Data sharing statement Insurance reimbursement claims data used in this study were available for public access. Patient identification numbers were scrambled to ensure confidentiality.

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.